First-in-human Evaluation Of A Novel Immunobiotic To Prevent Respiratory Infection
Funder
National Health and Medical Research Council
Funding Amount
$1,180,080.00
Summary
Respiratory infections are a leading cause of death and illness throughout the world. We have discovered a 'friendly' bacteria that can be applied up the nose to prevent ear infections and the 'flu in mice. We will now test this novel therapy in humans to check it is safe and that it stimulates the human immune system in the same way that it does in mice. This will provide essential information to conduct clinical trials, with the aim to produce a medicine that prevents respiratory infections.
Spinosyns As Endectocides For Blocking Transmission Of Malaria And Other Mosquito-borne Diseases
Funder
National Health and Medical Research Council
Funding Amount
$758,299.00
Summary
Malaria is a disease caused by a parasite. It is transmitted by mosquitoes and kills 400,000 people annually. To prevent malaria we must stop transmission. We have discovered a natural substance that, if ingested, makes an animal's blood lethal to at least one type of mosquito. It also kills the parasite. We aim to determine if it kills other key mosquito types and how it kills the parasite. We expect this study will lead to a pill that stops transmission of malaria and other tropical diseases.
Influenza A Viral Infection And Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$1,346,858.00
Summary
Pregnant women who contract influenza are 5 times more likely to be hospitalised than the general population. Babies of mothers with influenza are also associated with increased perinatal mortality rates. We hypothesise that influenza infection in pregnancy significantly impairs the maternal vascular system resulting in maternal and foetal morbidity. Outcomes from this research may change current treatment modalities to improve maternal and foetal outcomes complicated by influenza infection.
Oleoyl-ACP-hydrolase As An Early Predictive Biomarker For Severe And Fatal Influenza
Funder
National Health and Medical Research Council
Funding Amount
$866,807.00
Summary
Millions are hospitalized with severe influenza disease and ~500K die annually but the underlying mechanisms that drive disease are still not fully understood. We have identified a key role for an enzyme involved in fatty acid metabolism, which is profoundly elevated in patients who succumb to influenza and is thus a predictor for fatal outcomes. This research aims to investigate how this enzyme affects infection and impairs immune responses to drive severe respiratory viral disease.
Silencing Pulmonary Nociceptors To Treat Severe Respiratory Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$534,173.00
Summary
The lungs receive a rich supply of nerve fibres, many of which play an important role in helping defend against pathogens, including viruses. When viral infections become severe, too much inflammation occurs in the lungs and this creates a serious and difficult to treat clinical problem. Hundreds of thousands of people each year die from the complications of severe lung infections. We are investigating a potential new therapy that targets the lung nerves and relieves excessive inflammation.
Perinatal Microbe-host Interactions Regulate Neonatal Dendritic Cell Development
Funder
National Health and Medical Research Council
Funding Amount
$1,293,576.00
Summary
Acute lower respiratory tract infections (ALRI) are the leading cause of childhood mortality globally, and increase the risk of chronic lung diseases in later-life. Diverse communities of microorganisms - the microbiome - assemble in infancy and support immune development. In this study, we will explore the relationship between the microbiome and its metabolites, and the expression of an important hormone that regulates the development of the immune system to confer protection against ALRI.
Preservation And Generation Of Beta Cells In Type 1 Diabetes With Novel Mimetic Peptides
Funder
National Health and Medical Research Council
Funding Amount
$1,096,055.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease that destroys insulin producing beta cells in the pancreas. It can cause heart and kidney disease, and nerve damage. T1D is treated with insulin injections that can cause life-threatening low blood sugar levels. We have developed a new treatment that may stop beta cell loss, generate new beta cells and remove the need for insulin injections in T1D patients. A positive outcome will identify a completely new T1D treatment option.
Improving Clinical Outcomes Of Antimicrobial Resistant Infections With A Drug-free Intervention
Funder
National Health and Medical Research Council
Funding Amount
$999,581.00
Summary
Superbugs, or antimicrobial-resistant pathogens, cause recurring infections and non-healing wounds after surgery as existing therapies fail to effectively kill them. We will develop a medical device to fight superbugs with UV light that is effective against bacteria and fungi without causing harm to human cells. This could eradicate superbugs at infection sites, aid wound healing and actively improve health outcomes after surgery.
Modulating COVID-19 Disease By Targeting Virus And Virus-induced Responses Through Pharmaceutical And Mechanical Ventilation Strategies: SARS-CoV-2 S-protein, ACE2 And TMPRSS2
Funder
National Health and Medical Research Council
Funding Amount
$628,856.00
Summary
COVID-19 is a current global pandemic that is likely to be an on-going threat. We need a multipronged strategy to combat COVID-19, including therapeutic anti-virals and clinical practice management strategy. We will address both these points to define the mechanisms triggering disease, test existing drugs targeting androgens and modify the way doctors use ventilators to treat COVID-19 disease in the intensive care unit. Outcomes will have impact beyond COVID-19 for managing viral lung disease.
Development Of Novel Anti-malaria Drugs That Block Parasite Invasion
Funder
National Health and Medical Research Council
Funding Amount
$1,035,623.00
Summary
Malaria is a devastating parasitic disease that kills over 400,000 people a year. Antimalarial drugs play a crucial role in helping eradicate malaria but of great concern is that parasites are becoming resistant to current drugs. We are developing drugs that prevent parasites from invading and proliferating in human blood which causes malaria. We are also discovering how the drugs work with the aim of greatly improving their performance towards clinical uptake.